Assessment of clinical and laboratory presentations of familial hemophagocytic lymphohistiocytosis patients with homozygous W374X mutation

被引:14
|
作者
Balta, Gunay
Okur, Hamza
Unal, Sule
Yarali, Nese [2 ]
Gunes, Adalet Meral [3 ]
Unal, Selma [4 ]
Turker, Meral [5 ]
Gulerf, Elif [6 ]
Ertem, Mehmet [7 ]
Albayrak, Meryem [8 ]
Patiroglu, Turkan [9 ]
Gurgey, Aytemiz [1 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Pediat, Sect Pediat Hematol, TR-06100 Ankara, Turkey
[2] Diskapi SSK Educ & Res Hosp, Sect Pediat Hematol, Ankara, Turkey
[3] Uludag Univ, Dept Pediat, Sect Pediat Hematol, Bursa, Turkey
[4] Mersin Univ, Dept Pediat, Sect Pediat Hematol, Mersin, Turkey
[5] Tepecik SSK Educ Hosp, Sect Pediat Hematol, Izmir, Turkey
[6] Gaziantep Univ, Sect Pediat Oncol, Oncol Hosp, Gaziantep, Turkey
[7] Ankara Univ, Sect Pediat Hematol, Dept Pediat, TR-06100 Ankara, Turkey
[8] Gazi Univ, Dept Pediat, Sect Pediat Hematol, Ankara, Turkey
[9] Erciyes Univ, Dept Pediat, Sect Pediat Hematol, Kayseri, Turkey
关键词
Familial hemophagocytic lymphohistiocytosis; FHL; Perforin gene; W374X mutation; Clinical implications; Genotype-phenotype; Founder effect; PERFORIN GENE; TURKISH CHILDREN;
D O I
10.1016/j.leukres.2010.02.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Homozygous W374X mutation was identified in unrelated 13 patients (6M/7F) from consanguineous families, 62% of which had history of deceased sibling. Haplotype analysis provided evidence for the probable existence of a founder effect. Age at disease onset ranged from 1 day to 5.5 months (median 2 months). Hepatic dysfunction was observed in 69%, ascite 62%, hypertriglyceridemia 77%, each hyperferritinemia and hypofibrinogenemia 85%, CNS involvement 46% of patients while birth weights were in normal range. Those with very high ferritin (>20,000 ng/ml) had extremely low fibrinogen levels. Two-thirds of patients receiving HLH protocol died within 20 days of therapy. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1012 / 1017
页数:6
相关论文
共 34 条
  • [21] Structural and functional analysis of perforin mutations in association with clinical data of familial hemophagocytic lymphohistiocytosis type 2 (FHL2) patients
    An, Omer
    Gursoy, Attila
    Gurgey, Aytemiz
    Keskin, Ozlem
    PROTEIN SCIENCE, 2013, 22 (06) : 823 - 839
  • [22] Clinical and Laboratory Signs of Hemophagocytic Lymphohistiocytosis in Pandemic Influenza A (H1N1) Infection Patients Needing Extracorporal Membrane Oxygenation
    Greenwood, Tatiana von Bahr
    Holzgraefe, Bernhard
    Chiang, Samuel
    Wang, Yini
    Tesi, Bianca
    Bryceson, Yenan
    Henter, Jan-Inge
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S40 - S41
  • [23] Successful Treatment with Bone Marrow Transplantation in a Children with Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL3) with Mutation Homozygous c.9049G>A in Gen UNc13D
    Olaya Hernandez, Manuela
    Patino, Jaime
    Medina, Diego
    Perez, Paola
    Pachajoa, Harry
    Lotero, Viviana
    Serna, Lorena
    Silva, Nora
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 : S17 - S18
  • [24] Association of soluble interleukin-2 receptor alpha with laboratory parameters and clinical findings of hemophagocytic lymphohistiocytosis patients: The first report from south of Iran
    Shokripour, Mansoureh
    Mokhtari, Maral
    Samizadeh, Babak
    JOURNAL OF EDUCATION AND HEALTH PROMOTION, 2020, 9 (01)
  • [25] Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation
    Zimmermann, Nick
    Wolf, Christine
    Schwenke, Reiner
    Lueth, Anne
    Schmidt, Franziska
    Engel, Kerstin
    Lee-Kirsch, Min Ae
    Guenther, Claudia
    JAMA DERMATOLOGY, 2019, 155 (03) : 342 - 346
  • [26] D374Y MUTATION IN THE PCSK-9 GENE IN TURKISH PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: LONG TERM FOLLOW-UP WITH GOOD CLINICAL COURSE
    Kayikcioglu, M.
    Kocabas, E. K.
    Vardarli, A. T.
    Eroglu, Z.
    Dokmen, H.
    Salman, N.
    Payzin, S.
    Can, L. H.
    ATHEROSCLEROSIS, 2016, 252 : E36 - E36
  • [27] Clinical and laboratory findings in Hermansky-Pudlak Syndrome (HPS) patients homozygous for a 16-bp duplication in the HPS gene and patients not carrying this mutation.
    Gahl, W
    Brantly, M
    Hazelwood, S
    Kaiser-Kupfer, MI
    Iwata, F
    Bernardini, I
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A251 - A251
  • [28] Assessment of Surrogate Markers for Cardiovascular Disease in Familial Mediterranean Fever-Related Amyloidosis Patients Homozygous for M694V Mutation in MEFV Gene
    Sahin, Sezgin
    Romano, Micol
    Guzel, Ferhat
    Piskin, David
    Poddighe, Dimitri
    Sezer, Siren
    Kasapcopur, Ozgur
    Appleton, C. Thomas
    Yilmaz, Ilker
    Demirkaya, Erkan
    LIFE-BASEL, 2022, 12 (05):
  • [29] PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia
    Kaya, Esra
    Kayikcioglu, Meral
    Vardarli, Asli Tetik
    Eroglu, Zuhal
    Payzin, Serdar
    Can, Levent
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 18 (04): : 266 - 272
  • [30] Clinical spectrum of CMT4C disease in patients homozygous for the p.Arg1109X mutation in SH3TC2
    Colomer, Jaume
    Gooding, Rebecca
    Angelicheva, Dora
    King, Rosalind H. M.
    Guillen-Navarro, Encarna
    Parman, Yesim
    Nascimento, Andres
    Conill, Joan
    Kalaydjieva, Luba
    NEUROMUSCULAR DISORDERS, 2006, 16 (07) : 449 - 453